Export financials
Промомед (PRMD)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.

Промомед Cash Flow 2025-2021 | PRMD
Annual Cash Flow Промомед
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
Net Income |
7.04 B | 2.86 B | 2.97 B | 3.97 B | 3.38 B |
Depreciation And Amortization of Intangible Assets |
1.4 B | 1.1 B | 1 B | 600 M | 400 M |
Cash At End Of Period |
4.21 B | 4.08 B | 620 M | 2.14 B | 260 M |
Operating Cash Flow |
267 M | 93 M | -1.19 B | 2.96 B | 2.04 B |
Capital Expenditure |
4.56 B | 4.06 B | 4.43 B | 6.64 B | 3.24 B |
Free Cash Flow |
-4.29 B | -3.97 B | -5.62 B | -3.68 B | -1.2 B |
Annual performance
Select metrics to display
All numbers in RUB currency
Quarterly Cash Flow Промомед
| 2026-Q2 | 2025-Q4 | 2025-Q2 | |
|---|---|---|---|
Net Income |
2.5 B | 5.64 B | 1.4 B |
Depreciation And Amortization of Intangible Assets |
800 M | 700 M | 700 M |
Dividends Paid |
- | - | - |
Operating Cash Flow |
-1.8 B | 1.01 B | -743 M |
Capital Expenditure |
2.71 B | 3.16 B | 1.39 B |
Free Cash Flow |
-4.51 B | -2.15 B | -2.13 B |
Quarterly performance
Select metrics to display
All numbers in RUB currency
Cash Flow Statement is one of the three key financial reports of the company Промомед, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Biotechnology sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Cytokinetics, Incorporated
CYTK
|
$ 50.7 | -1.48 % | $ 6.09 M | ||
|
DBV Technologies S.A.
DBVT
|
$ 9.03 | -4.14 % | $ 1.26 B | ||
|
Precision BioSciences
DTIL
|
$ 7.37 | 6.66 % | $ 94.5 M | ||
|
Exelixis
EXEL
|
$ 64.59 | -1.88 % | $ 17.5 B | ||
|
Fennec Pharmaceuticals
FENC
|
$ 13.09 | -2.68 % | $ 374 M | ||
|
Cardiff Oncology
CRDF
|
$ 0.85 | -4.67 % | $ 56.8 M | ||
|
BioNTech SE
BNTX
|
$ 80.87 | -0.63 % | $ 19.5 B | ||
|
Alkermes plc
ALKS
|
$ 44.89 | -2.79 % | $ 7.39 B | ||
|
ANI Pharmaceuticals
ANIP
|
$ 68.6 | -0.77 % | $ 1.38 B | ||
|
AIM ImmunoTech
AIM
|
$ 0.11 | -7.75 % | $ 178 K | ||
|
AC Immune SA
ACIU
|
$ 1.98 | -7.28 % | $ 199 M | ||
|
Atara Biotherapeutics
ATRA
|
$ 6.51 | 2.6 % | $ 81.7 M | ||
|
Allogene Therapeutics
ALLO
|
$ 0.63 | -5.62 % | $ 139 M | ||
|
Altimmune
ALT
|
$ 1.33 | -6.03 % | $ 117 M | ||
|
AnaptysBio
ANAB
|
$ 46.65 | -1.58 % | $ 1.35 B | ||
|
Ascendis Pharma A/S
ASND
|
$ 252.39 | -1.39 % | $ 15.3 B | ||
|
Arcturus Therapeutics Holdings
ARCT
|
$ 7.42 | -2.37 % | $ 203 M | ||
|
Aurinia Pharmaceuticals
AUPH
|
$ 14.7 | -1.28 % | $ 1.98 B | ||
|
Autolus Therapeutics plc
AUTL
|
$ 0.91 | -6.96 % | $ 242 M | ||
|
Atea Pharmaceuticals
AVIR
|
$ 3.97 | 0.89 % | $ 324 M | ||
|
Axsome Therapeutics
AXSM
|
$ 129.32 | -4.69 % | $ 6.43 B | ||
|
BridgeBio Pharma
BBIO
|
$ 75.96 | -2.84 % | $ 14.5 B | ||
|
BioCryst Pharmaceuticals
BCRX
|
$ 7.23 | -1.3 % | $ 1.52 B | ||
|
Bicycle Therapeutics plc
BCYC
|
$ 2.89 | -5.25 % | $ 200 M | ||
|
Benitec Biopharma
BNTC
|
$ 7.95 | -2.4 % | $ 370 M | ||
|
DiaMedica Therapeutics
DMAC
|
$ 8.24 | 2.74 % | $ 387 M | ||
|
Insmed Incorporated
INSM
|
$ 141.06 | -2.35 % | $ 28.1 B | ||
|
Iovance Biotherapeutics
IOVA
|
$ 6.9 | -5.61 % | $ 2.47 M | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
$ 4.64 | 17.17 % | $ 56.6 M | ||
|
InMed Pharmaceuticals
INM
|
$ 15.56 | 13.57 % | $ 64.8 M | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$ 12.36 | -9.55 % | $ 799 M | ||
|
Immutep Limited
IMMP
|
$ 3.11 | -9.06 % | $ 4.53 B | ||
|
Jazz Pharmaceuticals plc
JAZZ
|
$ 228.26 | -3.46 % | $ 13.9 B | ||
|
BeyondSpring
BYSI
|
$ 0.33 | -24.42 % | $ 13.6 M | ||
|
Cabaletta Bio
CABA
|
$ 0.94 | -7.24 % | $ 94.5 M | ||
|
Johnson & Johnson
JNJ
|
$ 270.2 | 1.18 % | $ 650 B | ||
|
Cue Biopharma
CUE
|
$ 4.2 | -6.67 % | $ 398 M | ||
|
C4 Therapeutics
CCCC
|
$ 2.49 | 1.84 % | $ 206 M | ||
|
Codexis
CDXS
|
$ 1.0 | -5.17 % | $ 87.1 M | ||
|
Kamada Ltd.
KMDA
|
$ 7.75 | -1.02 % | $ 447 M | ||
|
Compugen Ltd.
CGEN
|
$ 1.83 | -2.66 % | $ 171 M | ||
|
Coherus BioSciences
CHRS
|
$ 0.37 | -4.06 % | $ 43.3 M | ||
|
Armata Pharmaceuticals
ARMP
|
$ 3.06 | 2.68 % | $ 111 M | ||
|
Celldex Therapeutics
CLDX
|
$ 27.36 | -2.15 % | $ 1.82 B | ||
|
Cellectis S.A.
CLLS
|
$ 0.9 | -9.7 % | $ 90.3 M | ||
|
Lineage Cell Therapeutics
LCTX
|
$ 0.78 | -4.87 % | $ 179 M | ||
|
Edesa Biotech
EDSA
|
$ 2.01 | -7.59 % | $ 11.4 M | ||
|
Eli Lilly and Company
LLY
|
$ 1 345.4 | -0.44 % | $ 1.21 T | ||
|
Collegium Pharmaceutical
COLL
|
$ 24.73 | -1.9 % | $ 783 M |